<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637646</url>
  </required_header>
  <id_info>
    <org_study_id>cardiac affections in MPS</org_study_id>
    <nct_id>NCT04637646</nct_id>
  </id_info>
  <brief_title>Evaluation of Cardiac Affections in Patients With Mucopolysaccharidosis (MPS) in Assuit University Children Hospital (AUCH)</brief_title>
  <acronym>MPS</acronym>
  <official_title>Evaluation of Cardiac Affections in Patients With Mucopolysaccharidosis (MPS) in Assuit University Children Hospital (AUCH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the different cardiac changes in the various types of MPS&#xD;
      disorder and define the outcome of these cardiac abnormalities in those patients admitted to&#xD;
      assuit University Children Hospital&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the&#xD;
      absence of functional enzymes that contribute to the degradation of glycosaminoglycans&#xD;
      (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction&#xD;
      that varies with the particular GAG deposited and the specific enzyme mutation(s) present.&#xD;
&#xD;
      Cardiac involvement has been reported in all MPS syndromes and is a common and early feature,&#xD;
      particularly for those with MPS I, II, and VI. Cardiac valve thickening, dysfunction (more&#xD;
      severe for left-sided than for right-sided valves), and hypertrophy are commonly present;&#xD;
      conduction abnormalities, coronary artery and other vascular involvement may also occur.&#xD;
      Cardiac disease emerges silently and contributes significantly to early mortality. The&#xD;
      clinical examination of individuals with MPS is often difficult due to physical and,&#xD;
      sometimes, intellectual patient limitations. The absence of precordial murmurs does not&#xD;
      exclude the presence of cardiac disease. Echocardiography and electrocardiography are key&#xD;
      diagnostic techniques for evaluation of valves, ventricular dimensions and function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">January 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Cardiac affection in patients with MPS</measure>
    <time_frame>on enrollment</time_frame>
    <description>cardiac affection in MPS patients</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Mucopolysaccharidoses</condition>
  <arm_group>
    <arm_group_label>children with MPS</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with mucopolysacchridosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - All the patients at any age up to 18 years with any type of MPS confirmed by the&#xD;
        enzymatic assay&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any patient other than MPS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>hager mohamed rageh, MBChB</last_name>
    <phone>01065007569</phone>
    <email>hagerdardiry@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Mahrous Sayed El-Talawy, PhD</last_name>
    <phone>01003486596</phone>
    <email>ohamed.mohamed51@med.au.edu.eg</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hager Rageh Dardiry</investigator_full_name>
    <investigator_title>researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

